Unexpectedly good earnings report.

CAI is one of the few IPO stocks this year that I would consider holding long-term. I have been following it since its first day.

A leader in the field of oncology, similar to TEM, the company aims to develop an early detection platform for diseases using blood samples, and there are high expectations for its use of genetic sequencing and AI in cancer diagnosis and treatment.

While monetization remains a significant challenge, yesterday's earnings results exceeded expectations with surprising revenue growth and an unexpected turnaround to operating profitability, delivering a strong earnings report.

I am also drawn to the passion and track record of the founder and CEO, David Dean Halbert, who boasts, 'Every company I’ve worked on has been successful,' and 'All investors should have made a profit.'

Will TEM holders become rivals? Personally, I think it would be interesting if CAI also supports them together. (This is a speculative stock, so proceed at your own risk. 💦)

Although both companies saw significant declines in their stock prices following strong earnings reports, I will continue to monitor them patiently.

As for TEM, it has grown considerably. 🌱